Hepatitis C Virus Treatment

Highly Effective Therapy with Direct Acting Antivirals and Associated Viral Resistance

Buch | Softcover

75 Seiten

2018 | Softcover reprint of the original 1st ed. 2017
Springer Verlag, Singapore
978-981-10-9610-5 (ISBN)

Artikel merken

This book introduces readers to Direct Acting Antiviral (DAAs) agents, newly developed drugs to treat chronic hepatitis C virus infection, which have an excellent anti-viral effect on virus replication. These drugs have been developed to enhance the effect of interferon and ribavirin, as the resistant strains against each drug have been described both in vitro and in vivo and the existences of naturally occurring variants have been reported. However, since the combination of different classes of DAAs is sufficient to completely eradicate the virus without the need for interferon or ribavirin, the current treatment regimen does not include interferon. Ribavirin is used in combination with sofosbuvir, a potent polymerase inhibitor, to enhance its antiviral effects.

Hepatitis C Virus Treatment offers readers a comprehensive guide to hepatitis C; describing the resistance profiles against these drugs and shedding light on the difficulties involved in DAA therapy and the direction of future treatments, it will equip doctors to understand the essentials of treating the disease. It also describes in detail new and innovative DAA treatments, the effects of the agents, and the characteristics of resistance, providing cutting-edge information not only for hepatologists, but also for researchers, clinical residents, and medical students.

Prof. Kazuaki ChayamaDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University

Preface The first generation protease inhibitor Telaprevir and the emergence of antiviral resistance Features of the second wave of the first generation protease inhibitors: effect and tolerance Effects and resistance risks of combination treatment with Daclatasvir + Asunaprevir: the first approved oral agent without IFN and ribavirin Resistance features of NS5A inhibitors and methods for detection Detection of naturally occurring variants with resistance features against antiviral drugs Incidence and characteristics of naturally occurring resistant strains Characteristics and resistance profiles of polymerase inhibitors Emerging antivirals in the future

Erscheinungsdatum	27.08.2018
Zusatzinfo	14 Illustrations, color; 9 Illustrations, black and white; VII, 75 p. 23 illus., 14 illus. in color.
Verlagsort	Singapore
Sprache	englisch
Maße	155 x 235 mm
Themenwelt	Medizinische Fachgebiete ► Innere Medizin ► Hepatologie
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Mikrobiologie / Infektologie / Reisemedizin
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
	Naturwissenschaften ► Biologie ► Mikrobiologie / Immunologie
Schlagworte	Chronic liver disease • DAA • Direct Acting Antiviral Agents • HCV • immunity • Infection • Interferon • Polymerase Inhibitor • Protease inhibitor • Resistance Mutations • Ribavirin • Telaprevir
ISBN-10	981-10-9610-4 / 9811096104
ISBN-13	978-981-10-9610-5 / 9789811096105
Zustand	Neuware